Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, played an integral role in the clinical research that first gained FDA approval in June 2024, and has now led to the European Union’s approval of Ipsen’s Iqirvo, a groundbreaking therapy for primary biliary cholangitis (PBC), a rare liver condition. As the lead investigator for the Phase 3 … Read more
Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema). mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV. Livdelzi … Read more
In this new article for VentureBeat, Raghu Punnamraju, Chief Technology Officer at Velocity, discusses why data science alone is not enough to ensure product success. In this insightful piece, Raghu explores the importance of blending technical excellence with commercial understanding, highlighting the need for lean-value principles, the role of AI, and the power of data … Read more
Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is in the same place as most people with AI. We’ve seen a step change. Everybody started with efficiency gains, back-office functions. Then you move on … Read more
Brandon Essink, MD, CPI, and J. Scott Overcash, MD, were authors of a recent Nature Communications article, “Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.” From the article: “Boosting elicited greater immune responses against SARSCoV-2 than primary vaccination, irrespective of prior SARS-CoV-2 infection. Primary vaccination and boosting with … Read more
Since launching in-app stipend payments, Velocity has paid more than $2 million to patients globally through VISION. The mobile app has also contributed to more than 2,500 patient randomizations, empowering users to get matched with clinical trials, self-screen, and self-schedule visits, all at times that are most convenient for them. Together, VISION Engage and VISION … Read more
Another milestone for patients with primary biliary cholangitis (PBC) — Gilead’s Livdelzi® (seladelpar) has received accelerated FDA approval as a second-line treatment for PBC. Kris Kowdley, MD, AGAF, FAASLD, FACP, FAC, was an author of the Phase 3 trial results published in the New England Journal of Medicine. Congratulations to Gilead, Dr. Kowdley, the team … Read more
It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. This marked a turning point in the disease’s treatment, a drug that interrupted progression for the first time rather than simply addressing the symptoms. It was this type of breakthrough that Robert … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K. Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of Velocity’s European executive team to expand the company’s footprint in the … Read more
Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024. These include, but are not limited to: Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first FDA-approved #MASH drug. Moderna’s mRESVIA, an mRNA RSV vaccine for adults 60 and older. Eli Lilly and Company’s Kisunla (donanemab) for patients with early … Read more